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Background & Aims: The published risk of adenocarci-
noma in the setting of Barrett’s esophagus (BE) varies.
Publication bias, the selective reporting of studies fea-
turing positive or extreme results, may result in overes-
timation of this cancer risk in the literature. The aim of
this study was to assess those publications reporting a
cancer risk in BE for evidence of publication bias.
Methods: A MEDLINE search for all published estimates
between 1966 and 1998 of cancer risk in BE was per-
formed. All studies reporting a cancer risk expressible in
cancers per patient-year of follow-up were retrieved.
Bibliographies of these studies were surveyed for addi-
tional estimates. All publications that required an initial
endoscopy with histologic confirmation of BE and any
cancer were included. The relationship of reported can-
cer risk to size of the study was assessed. Multivariable
regression controlling for differences in definition of BE,
as well as other study characteristics, was performed.
The data were also analyzed by means of a funnel
diagram, an epidemiologic method to assess publica-
tion bias. Results: Five hundred fifty-four abstracts were
reviewed. Twenty-seven publications met the stated cri-
teria for inclusion. There was a strong correlation be-
tween cancer risk and the size of the study, with small
studies reporting much higher risks of cancer than larger
studies. This association persisted when differences in
the definition of BE, retrospective vs. prospective nature
of the study, surveillance interval, and the effect of
cancer detected in the first year were considered. The
funnel diagram analysis suggested publication bias.
Conclusions: The cancer risk in BE may be overesti-
mated in the literature due to publication bias.
Barrett’s esophagus (BE) is a metaplastic change of thelining of the esophagus with replacement of the
normal squamous mucosa by columnar intestinal-type
mucosa.1 Patients with chronic gastroesophageal reflux
disease (GERD) appear to be especially susceptible to
BE. Because BE is known to be associated with an
increased risk of adenocarcinoma of the esophagus,
guidelines have been proposed for endoscopic screening
of patients with long-standing reflux symptoms for the
presence of BE.2 Those patients found to have BE on
screening examinations would then be enrolled in endo-
scopic surveillance programs to monitor for dysplastic
changes by periodic endoscopy. Despite the lack of clin-
ical evidence showing a survival advantage in BE patients
enrolled in endoscopic surveillance programs, this prac-
tice has become the standard of care.
The cost-effectiveness of endoscopic surveillance pro-
grams is unclear. BE is a common condition among those
with frequent GERD, with a prevalence of approxi-
mately 10% of patients.3,4 Conversely, adenocarcinoma
of the esophagus is a rare cause of cancer in the United
States, with less than 10,000 cases nationwide in 1999.
One of the primary determinants of the cost-effectiveness
of surveillance strategies for BE is the underlying inci-
dence of cancer among patients with BE.5 If the cancer
incidence is high, then surveillance should be relatively
cost-effective, with relatively few dollars spent per can-
cers detected. If the cancer incidence is low, then many
endoscopies might be required to find one lesion, and
cost-effectiveness will be poor. Unfortunately, estimates
of cancer risk in BE are highly heterogeneous, ranging
from 0% to almost 3% per patient-year.
Publication bias is the selective reporting of studies
featuring positive or extreme results. This bias has been
suggested in a variety of clinical situations,6–9 and may
result in misleading conclusions with respect to treat-
ment effects or risk estimation. Additionally, meta-anal-
ysis of biased data may result in skewed conclusions.
Finally, patients may be asked to enroll in studies to
assess effectiveness of treatments already shown to be
ineffective or even harmful.10
Abbreviations used in this paper: BE, Barrett’s esophagus; GERD,
gastroesophageal reflux disease.




The purpose of this study was to systematically assess
for publication bias in the reporting of the cancer risk in
BE. If negative studies were less likely to be published,
then the published literature might exaggerate the risk
of adenocarcinoma, and overstate the potential value of
screening and surveillance programs for BE.
Materials and Methods
Study Selection and Data Abstraction
We assessed the English language literature for pub-
lications reporting a risk estimate for adenocarcinoma of the
esophagus in the setting of BE. Computerized MEDLINE was
used to assess publications from 1966 and 1998. The 2 main
search strategies combined the keywords “Barrett’s esophagus”
with either “adenocarcinoma” or “esophageal neoplasms.” All
abstracts retrieved by this search strategy were reviewed. Those
works reporting a cancer risk in the setting of BE were
retrieved. The bibliographies of these articles were then
scanned to identify additional articles for inclusion.
The authors used the following criteria for inclusion in the
study: (1) any journal article or text reporting a cancer risk
expressible in cancers per patient-year of follow-up; (2) endos-
copy with biopsy at baseline for any patient included in the
cohort; (3) histologic confirmation of BE of all patients in the
cohort; and (4) histologic confirmation of any cancers during
the follow-up period.
Estimates published solely in abstract form, as well as those
with inadequate information to assess the previous criteria,
were excluded. Published studies were abstracted by 2 inves-
tigators independently. Variables assessed included: year of
publication, country of origin, cancer risk, retrospective vs.
prospective design, endoscopic surveillance interval (catego-
rized into 1 year, 2 years, .2 years, and no set interval), and
number of cancers developing in the first year of follow-up.
Because the definition of BE used by investigators varies, the
pathologic definition of BE (categorized into specialized/intes-
tinal, any columnar, and not specified), as well as length
criteria of BE (categorized into columnar epithelium of any
length, .2 cm, .3 cm, other, and not specified) were also
recorded. When noted, the percentage of patients undergoing
a surgical antireflux procedure was also recorded. If serial
publications reported cancer risk in the same cohort of pa-
tients, only the most recent report was included in the analysis.
Data Analysis
Cancer risks were calculated by dividing the number of
cancers observed by the total number of patient-years of ob-
servation. Patients developing carcinoma were censored and no
longer eligible to contribute patient-years of observation after
their diagnosis. The agreement of abstracted data between
investigators was assessed using the k statistic.
Simple linear regression was used to assess the relationship
between the size of the study (reported in cumulative patient-
years of follow-up), and the reported cancer risk. Multivariable
regression was performed to assess this relationship, control-
ling for other potentially confounding variables including year
of publication, definition of BE, proportion of patients with
surgical antireflux procedures, endoscopic surveillance interval,
and retrospective vs. prospective study. No more than 3 pre-
dictor variables were assessed simultaneously. All regression
analysis was performed using STATA 6.0 programs (College
Station, TX).
Assessment of publication bias was performed using a mod-
ified funnel diagram.11,12 This is a graphic approach in which
the size of the study (in this case the cumulative patient-years
of follow-up of patients with BE) is plotted on the y-axis, and
the measure of effect (here, the reported cancer risk) is plotted
on the x-axis. Because sampling error decreases as sample size
increases, the cancer risk estimate should become more precise
as the studies get larger. Therefore, when no publication bias
exists, the smaller studies should be scattered evenly around
the base of the funnel, and the larger studies should narrow to
a point that approximates the true population risk (Figure 1).
Conversely, when publication bias occurs, there may be selec-
tive publication of only those reports featuring high risks. In
that case, there may be a “hole” in the base of the funnel, where
smaller studies reporting more modest risks go unreported
(Figure 2).
Results
Five hundred fifty-four abstracts were reviewed.
Twenty publications met the stated criteria for inclusion.
Of the remaining 534 abstracts, 530 dealt with other
aspects of the association of carcinoma with BE, 2 re-
ported combined incidences of dysplasia and cancer, and
2 did not have histologic data. Review of the bibliogra-
phies of the 20 retrieved articles yielded an additional 7
articles for inclusion. Two of these articles represented
serial reports of the same cohort. Therefore, a total of 25
articles were included in the final analysis.13–37 Agree-
Figure 1. Sample funnel diagram showing no publication bias. “True”
risk is 5. Estimated risks disperse evenly around “true” risk, with
larger studies providing more accurate estimates.
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ment for study inclusion between the reviewers was high
(k 5 0.82).
Table 1 lists the studies analyzed, with the journal,
year of publication, number of studies, cumulative pa-
tient-years of follow-up, incident cancers, age, and gen-
der distribution. There was no correlation between year
of publication and reported cancer risk. Additionally,
cancer risk was not associated with the definition of BE,
length criteria for BE, retrospective vs. prospective nature of
the study, or proportion of patients undergoing surgical
antireflux procedures. However, reported cancer risk was
strongly associated in a negative curvilinear relationship
with the size of the study (P , 0.01; Figure 3).
A funnel diagram was constructed by plotting the
study size against the natural log of the reported cancer
incidence (Figure 4). This diagram showed a paucity of
small studies expressing low cancer risks.
Figure 2. Sample funnel diagram suggesting publication bias. “True”
risk is still 5. Estimated risks now collect at higher values for small
studies, suggesting bias against publishing small studies with low
risks.
Table 1. Publications Reporting the Risk of Esophageal Adenocarcinoma in Barrett’s Esophagus






age (yr ) Female (%)
Achkar and Carey13 Am J Gastroenterol 1988 62 166 1 56 26
Bartelsman et al.14 Eur J Cancer Prev 1992 50 260 5 n/a n/a
Cameron et al.15 N Engl J Med 1985 104 882 2 60 31
Cooper and
Barbezat16 Q J Med 1987 52 45 0 63 38
Csendes et al.17 Surgery 1998 151 1147 4 52 35
Drewitz et al.18 Am J Gastroenterol 1997 170 834 4 62 2
Ferraris et al.19 Eur J Gastroenterol Hepatol 1997 187 562 3 n/a n/a
Hameeteman et al.20 Gastroenterology 1989 50 260 5 59 40
Iftikhar et al.21 Gut 1992 102 462 4 63 39
Katz et al.22 Am J Gastroenterol 1998 102 563 3 63 17
McDonald et al.23 J Thorac Cardiovasc Surg 1996 112 728 3 68 31
Miros et al.24 Gut 1991 81 290 3 63 25
Moghissi et al.25 Eur J Cardiothorac Surg 1993 26 299 4 62 31
Ortiz et al.26 Br J Surg 1996 59 287 2 37 32
Ovaska et al.27 Dig Dis Sci 1989 32 166 3 59 31
Reid et al.28 Gastroenterology 1992 62 176 5 62 18
Robertson et al.29 Br J Surg 1988 56 168 3 62 45
Savary et al.30 Text 1984 402 1528 5 n/a n/a
Skinner31 Text 1989 45 145 3 n/a n/a
Spechler et al.32 Gastroenterology 1984 105 350 2 n/a n/a
Streitz et al.33 Am J Gastroenterol 1998 149 510 7 n/a n/a
van der Burgh et al.34 Gut 1996 155 1440 8 62 42
Watson et al.35 Eur J Gastroenterol Hepatol 1991 45 158 1 63 51
Weston et al.36 Am J Gastroenterol 1997 55 94 2 63 24
Williamson et al.37 Arch Intern Med 1991 176 497 5 56 35
n/a, not available.
Figure 3. Reported cancer risk in BE vs. size of study.
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Discussion
This study shows an inverse relationship between
study size and reported cancer risk in the setting of BE.
One possible explanation for this observation is that
publication bias has occurred. Investigators with small
studies demonstrating modest cancer risks may be reluc-
tant to submit these findings for publication because of
fear of rejection. Alternatively, editors may feel that
small negative studies are not newsworthy, whereas small
studies showing high risks may be more appealing.
There are other potential reasons for this observation.
Perhaps the studies vary in some systematic way, such
that the smaller studies encompass patients at higher risk
for carcinoma than the large studies. For instance, if the
smaller studies included only those patients with intes-
tinal-type epithelium, whereas the larger studies in-
cluded patients with any columnar epithelium, the
smaller studies might be expected to show a higher risk
of neoplasia. However, in multivariable regression, def-
inition of BE, length of BE, proportion of surgically
altered patients, country of origin, and retrospective vs.
prospective design of the study were not found to be
significantly associated with the reported cancer risk.
Furthermore, although the risk of adenocarcinoma of the
esophagus appears to be rising,38 controlling for the year
of publication did not alter the relationship between
study size and cancer risk. Therefore, it seems unlikely
that some other methodologic or demographic feature of
the studies accounts for the observed association between
study size and cancer risk. Similarly, temporal changes in
the epidemiology of adenocarcinoma of the esophagus do
not explain these findings.
Detection bias might also explain the association of
cancer risk and study size. This bias might be shown in
multiple ways. First, if smaller studies also had more
intense endoscopic surveillance protocols, more cancer
cases might be detected. However, there was no signif-
icant relationship between endoscopic surveillance inter-
val and either study size or cancer risk. Second, patients
in the smaller studies had a shorter mean follow-up
period. If the initial endoscopy missed an already exist-
ing cancer, the number of incident cancers in the fol-
low-up period might be artificially inflated by the inclu-
sion of these missed prevalent cancers. Because the
smaller studies have fewer follow-up years per patient,
there would be less dilution of the effect of missed
prevalent cancers. To assess the importance of missed
prevalent cancers, we reanalyzed the data after excluding
all carcinomas diagnosed in the first year of follow-up in
those studies providing longitudinal data (n 5 18).
Excluding these cases did not affect the strong inverse
relationship between study size and reported cancer risk.
The use of a funnel diagram to assess for publication
bias implies several assumptions. First, we must assume
that large studies reporting modest cancer risks are less
likely to be suppressed by either authors or editors than
similar small studies. Although this makes intuitive
sense, this assumption cannot be evaluated.39 Addition-
ally, this technique is primarily graphic, as opposed to
quantitative, and funnel plots may be interpreted differ-
ently by different investigators. Previous attempts have
been made to assess funnel plot asymmetry numerically;
however, the validity of these approaches has been ques-
tioned.40 Next, data retrieval from the literature must be
thorough. Although rigorous attempts were made to
locate all studies conforming to our criteria, it is possible,
and perhaps likely, that some studies escaped our no-
tice.41 Finally, funnel plot techniques imply no assess-
ment of study quality beyond the criteria defined by the
researcher for study inclusion. Although large studies are
often of higher methodologic quality than smaller stud-
ies, this is not universally true. In the present study,
studies appearing solely in abstract form were not eligi-
ble for inclusion. Although such data are important, the
lack of information in abstracts with respect to demo-
graphics, definition of BE, surveillance protocols, surgi-
cally altered patients, and other potential confounders
made the previously mentioned analysis untenable using
these data. There is also the theoretical concern that data
appearing solely as abstracts may be of poorer quality
than those published in journals.
The presence of possible publication bias in the assess-
ment of the cancer risk in BE has several implications.
Although widely practiced, periodic endoscopic surveil-
lance of patients with BE has not been shown to decrease
cancer incidence or increase life expectancy. Previous
Figure 4. Modified funnel diagram of cancer risk in BE.
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investigators modeling the utility of endoscopic surveil-
lance of patients with BE have shown that the underlying
incidence of adenocarcinoma of the esophagus is a pri-
mary determinant of the cost-effectiveness of endoscopic
surveillance.5,33 If this incidence is lower than previously
thought, we might be overemphasizing the benefit of
costly screening programs. Additionally, several investi-
gators have combined data from studies reporting cancer
risk in BE in an attempt to generate a summary statistic
of cancer risk.18,33 Such mixing of heterogeneous esti-
mates from large and small studies in meta-analysis may
result in inflated estimates of cancer risk. Although the
results of this study do not allow for the ascertainment of
the cancer risk in BE, the point of the funnel appears to
be at an incidence of approximately 0.5% per patient-
year.
In conclusion, in studies reporting the incidence of
adenocarcinoma of the esophagus in the setting of BE,
there is a strong inverse relationship between the size of
the study and the reported cancer risk. Potential con-
founders, such as date of publication, definition of Bar-
rett’s used, proportion of patients with surgical antireflux
procedures, and inclusion of prevalent cases, do not ap-
pear to explain this association. Publication bias, such
that smaller studies are published only if they feature
high cancer risks, is a possible explanation for the ob-
served association. Policy makers wishing to create pa-
tient care guidelines based on the literature should be
aware of this potential bias.
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